Literature DB >> 9570382

Estrogen receptor-negative/progesterone receptor-positive Evsa-T mammary tumor cells: a model for assessing the biological property of this peculiar phenotype of breast cancers.

M Borras1, M Lacroix, N Legros, G Leclercq.   

Abstract

In 1986 we reported the appearance of a progestin binding protein in the human breast cancer cell line Evsa-T, originally described as lacking both estrogen and progesterone receptors (ER and PR). In this report we show that PR of this cell line displays a binding affinity for [3H]ORG 2058 and a sucrose gradient sedimentation profile similar to those ascribed to PR from MCF-7 or T47D breast cancer cell lines. PR from Evsa-T cells is down-regulated by the progestin R-5020 as well as by the two antiprogestins, ZK 112.993 and ZK 98.299, but does not confer growth sensitivity to these compounds. ER remains undetectable by ligand binding assay, enzyme immunoassay and northern blotting. Our Evsa-T clone could be a valuable model for assessing the mechanisms leading the ER-/PR+ phenotype occurring occasionally in breast cancers and frequently in meningiomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9570382     DOI: 10.1016/s0304-3835(97)00285-1

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  4 in total

1.  Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer.

Authors:  Hongjuan Zheng; Chenyang Ge; Haiping Lin; Lunpo Wu; Qinghua Wang; Shishi Zhou; Wanfen Tang; Xia Zhang; Xiayun Jin; Xifeng Xu; Zhongwu Hong; Jianfei Fu; Jinlin Du
Journal:  Int J Clin Oncol       Date:  2022-04-10       Impact factor: 3.402

2.  Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment.

Authors:  Ke-da Yu; Gen-hong Di; Jiong Wu; Jin-song Lu; Kun-wei Shen; Guang-yu Liu; Zhen-zhou Shen; Zhio-ming Shao
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-17       Impact factor: 4.553

3.  Estrogen receptor of primary breast cancers: evidence for intracellular proteolysis.

Authors:  Y Maaroufi; M Lacroix; L Lespagnard; F Journé; D Larsimont; G Leclercq
Journal:  Breast Cancer Res       Date:  2000-09-06       Impact factor: 6.466

4.  Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer.

Authors:  Ke-Da Yu; Yi-Zhou Jiang; Shuang Hao; Zhi-Ming Shao
Journal:  BMC Med       Date:  2015-10-05       Impact factor: 8.775

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.